banner

Tag Archives: Intellectual Property

no menu

FDA Announces First-Ever Patient Engagement Advisory Committee

Recently, the FDA announced the formation of the Patient Engagement Advisory Committee (PEAC) and requested public comments on what topics the committee should consider, which are due November 20th. FDA also published three requests for nominations to serve on the committee, including one for industry members which is due October 21st.


CLSA Efforts to Protect Patents Gain Momentum

CLSA is actively opposing H.R. 9, the so-called Innovation Act, legislation that contains patent litigation-related provisions that would threaten the ability of biomedical innovators to enforce their patents and fund continued R&D by making it more difficult, time-consuming and expensive to enforce legitimate and important IP rights.



CLSA Continues to Engage with California Delegation to Protect Patent Rights, Oppose H.R. 9

CLSA is actively opposing H.R. 9, the so-called Innovation Act, legislation that contains patent litigation-related provisions that would threaten the ability of biomedical innovators to enforce their patents and fund continued R&D by making it more difficult, time-consuming and expensive to enforce legitimate and important IP rights. We continue to work stakeholders and members of the California congressional delegation to advocate for changes to the legislation that would both strengthen patent protections and curb abusive litigation practices by “patent trolls” for all patent holders and industry sectors.


Congress Passes Crucial US Trade Promotion Authority (TPA) Legislation

On June 18, the House passed critical legislation to renew the Trade Promotion Authority (TPA) by a vote of 218 to 208. The Senate also moved to passed TPA, by a vote of 60 to 38 on June 24. CLSA was supportive of H.R. 2146, the Trade Priorities and Accountability Act, and worked with the California delegation in informing them of the important provisions in TPA that would allow the Administration to better protect IP rights and fair market access when negotiating trade deals.